Bayer
RedHill Biopharma's Opaganib Enters Phase II Trial With Nubeqa in Select Prostate Cancer Patients
Researchers will use a lipidomic biomarker test to select patients with a poor prognosis who may benefit from an investigational combination therapy.
Tissue-Agnostic Trial Shows Frontline Vitrakvi Benefit in NTRK-Positive Pediatric Solid Tumors
In the Phase II ADVL1823 study, researchers evaluated Vitrakvi in children with newly diagnosed IFS and other solid tumors with NTRK fusions.
Belief BioMed, Bayer's AskBio to Collaborate on Liver-Targeted Gene Therapies
As part of the deal, the companies said they will work together to advance gene therapies for diseases with high unmet medical need.
Bayer Begins Phase III Trial of EGFR, HER2 Inhibitor in First-Line HER2-Mutant NSCLC
The firm will compare how BAY 2927088 impacts progression-free survival compared to Keytruda plus chemo in around 280 patients.
FDA Approves Illumina Cancer Genomic Profiling Assay as CDx for Kinase Inhibitors From Bayer, Lilly
The test's first CDx approvals are for Bayer's Vitrakvi in solid tumors and for Lilly's Retevmo in non-small cell lung cancer.